Despite Softness in Q1, Qiagen Expects HPV Business to Bounce Back This Year | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – In the midst of reporting soft first-quarter earnings results that failed to meet Wall Street expectations, Qiagen officials today continued to be optimistic that the company will meet its full-year 2011 guidance with a bounceback in its human papillomavirus business, new revenue streams from its pending Cellestis acquisition, and the development of new assays and platforms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.